Anticoagulant Reversal Drugs Market Size Worth $1.81 Billion By 2027: Grand View Research, Inc.

Anticoagulant Reversal Drugs Market Size Worth $1.81 Billion By 2027: Grand View Research, Inc.

PR Newswire

SAN FRANCISCO, Feb. 22, 2021

SAN FRANCISCO, Feb. 22, 2021 /PRNewswire/ -- The global anticoagulant reversal drugs market size is expected to reach USD 1.81 billion by 2027, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 14.3% from 2020 to 2027. The rising number of bleeding disorders, the introduction of new drugs, and the growing number of cases requiring anticoagulant therapies are some of the factors anticipated to foster market growth during the forecast period.


Key suggestions from the report:

Read 110 page research report with ToC on "Anticoagulant Reversal Drugs Market Size, Share & Trends Analysis Report By Product Type (Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, Idarucizumab, Protamine), By Distribution Channel, And Segment Forecasts, 2020 - 2027" at:

In October 2015, Praxbind (idarucizumab) by Boehringer Ingelheim Pharmaceuticals was approved as an anticoagulant reversal drug indicated for patients treated with Pradaxa (dabigatran) during emergency surgery or uncontrolled or life-threatening bleeding. Hence, the availability of these anticoagulation reversal drugs allows doctors and patients to consider such treatment options with greater confidence, therefore boosting the demand for anticoagulant reversal drugs.

Bleeding disorders like hemophilia can be acquired or inherited. However, other bleeding disorders can occur from conditions, such as HIV, anemia, leukemia, cirrhosis of the liver, and vitamin K deficiency. According to the National Heart, Lung, and Blood Institute, more than 3 million people in the U.S. are affected with anemia, which is the most common blood disorder. The Leukemia & Lymphoma Society (LLS) stated that in the year 2020, the number of people expected to be diagnosed with leukemia is around 60,530. A rise in bleeding disorders is increasing the demand for anticoagulants, thus fueling the market growth.

However, the high cost of these reversal therapies is anticipated to restrain the market growth. As per the American College of Cardiology, 4-F PCC (Kcentra) helps in treating bleeding cases caused by rivaroxaban and apixaban and it is dosed at 50 units/kg. Its average wholesale price is USD 2.90 per unit, therefore treating a patient whose weight is 100 kg would cost around USD 14,500.

Grand View Research has segmented the global anticoagulant reversal drugs market on the basis of product type, distribution channel, and region:

List of Key Players of Anticoagulant Reversal Drugs Market

Find more research reports on Pharmaceuticals Industry, by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.


Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Follow Us: LinkedIn | Twitter 


Voltar noticias em Inglês